New Biological Tests in Patients With Antiphospholipid Antibodies

Launched by HOSPICES CIVILS DE LYON · Mar 22, 2019

Keywords

ClinConnect Summary

This clinical trial is studying ways to better understand the risk of blood clots in patients with Antiphospholipid Syndrome (APS), an autoimmune disease that can cause serious complications like blood clots or pregnancy issues. Researchers want to see how two specific blood tests—one that measures thrombin generation (a key factor in blood clotting) and another that detects certain antibodies—can help predict the likelihood of these complications in patients who have tested positive for antiphospholipid antibodies. By comparing the results of these tests with patients' medical histories, the goal is to find better ways to assess and manage their risk of thrombosis (blood clots).

To participate in this trial, individuals must be adults aged 18 and older who have confirmed antiphospholipid antibodies, ensuring they meet specific criteria. Participants will undergo blood tests to evaluate these new assays, and their results will be carefully analyzed in relation to their past experiences with blood clots or pregnancy complications. It’s important to note that those currently on certain anticoagulant medications, or with specific medical conditions like liver disease or low platelet counts, will not be eligible for this study. This research is currently recruiting participants and aims to improve the understanding and treatment of APS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with confirmed aPL-Abs (at least two positive determinations at least 12 week apart)
• • Subject non opposition
• Exclusion Criteria:
• • Age \< 18 years
• • Patient under the protection of justice, under guardianship or under curatorship
• • Patient with anticoagulant treatment, except heparin
• • Clinically symptomatic liver disease, supported by e.g. diagnosis of cirrhosis, portal hypertension, ascites, PT superior or egal to 5 seconds above upper normal limit
• • Platelet count \< 100 G/L (giga/liter)
• • Poor venous access
• • Non confirmed suspicion of APS